PharmaCept is the worldwide leader on the temporary embolization area. Our Degradable Starch Microspheres (DSM) product, EmboCept® S DSM 50 µm, is well-established for Transarterial Chemoembolization (DSM-TACE). This agent can be combined with common cytostatic agents like PharmaCept’s Cisplatin powder PlatiCept®, which is unique in Europe. PharmaCept underlines its commitment to find the best patient-focus therapy options by its continuous support and execution of clinical investigations. Based on the trustful collaboration with international teams of physicians and key opinion leaders, we are able to substantiate the products’ benefits by clinical evidence. We will continue striving for ongoing therapy improvement in cancer treatment to further accomplish our company claim, “PharmaCept - Closer to Health”. PharmaCept was founded in the heart of Berlin, Germany, in 1999 and stands for the successful development and worldwide distribution of niche products for various cancer indications with a special focus on research in Interventional Oncology. During the last years we were able to offer physicians with a product portfolio enabling them to provide their patients with the best therapy options available.